Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.

"Declarations Ethics approval and consent to participateThe analysis of the study data has been approved by the IRB of Nihon University Itabashi Hospital, Clinical Research Ethics Committee and the IRBs of the participating hospitals. Informed consent was obtained from all individual participants included in the study. Consent for publicationNot applicable. Competing interestsS.M. has no relationships relevant to the content of this study. Y.O. received lecture fees from Bayer Yakuhin, Ltd., Bristol-Myers Squibb, and AstraZeneca K.K.; lecture fees, scholarship funds, and donations from Daiichi-Sankyo Co., Ltd.; scholarship funds and donations from Nihon Medi-Physics; and is associated with endowed departments sponsored by Boston Scientific Japan, Abbott Medical Japan, Medtronic Japan Co., Ltd., Nihon Kohden Co., and Japan Lifeline Co., Ltd. I.F. has no relationships relevant to the content of this study. M.N. has no relationships relevant to the content of this study. N.Y. received lecture fees from Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Daiichi-Sankyo Co., Ltd. M.T. has no relationships relevant to the content of this study. H.M. has no relationships relevant to the content of this study. Ta.Y. received lecture fees, manuscript fees, and research funding from Daiichi-Sankyo Co., Ltd., Bristol-Myers Squibb, and Bayer Yakuhin Ltd.; lecture fees from Ono Pharmaceutical Co., Ltd., Toa Eiyo, Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; and scholarships from Daiichi-Sankyo Co., Ltd. T.I. received lecture fees from Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., and Pfizer Japan Inc. and research funding from Daiichi-Sankyo Co., Ltd. M.M. received lecture fees from Bayer Yakuhin, Ltd. Ts.Y. has no relationships relevant to the content of this study. A.H. received lecture fees from Daiichi-Sankyo Co., Ltd. and Bayer Yakuhin, Ltd. Competing interests S.M. has no relationships relevant to the content of this study. Y.O. received lecture fees from Bayer Yakuhin, Ltd., Bristol-Myers Squibb, and AstraZeneca K.K.; lecture fees, scholarship funds, and donations from Daiichi-Sankyo Co., Ltd.; scholarship funds and donations from Nihon Medi-Physics; and is associated with endowed departments sponsored by Boston Scientific Japan, Abbott Medical Japan, Medtronic Japan Co., Ltd., Nihon Kohden Co., and Japan Lifeline Co., Ltd. I.F. has no relationships relevant to the content of this study. M.N. has no relationships relevant to the content of this study. N.Y. received lecture fees from Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Daiichi-Sankyo Co., Ltd. M.T. has no relationships relevant to the content of this study. H.M. has no relationships relevant to the content of this study. Ta.Y. received lecture fees, manuscript fees, and research funding from Daiichi-Sankyo Co., Ltd., Bristol-Myers Squibb, and Bayer Yakuhin Ltd.; lecture fees from Ono Pharmaceutical Co., Ltd., Toa Eiyo, Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; and scholarships from Daiichi-Sankyo Co., Ltd. T.I. received lecture fees from Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., and Pfizer Japan Inc. and research funding from Daiichi-Sankyo Co., Ltd. M.M. received lecture fees from Bayer Yakuhin, Ltd. Ts.Y. has no relationships relevant to the content of this study. A.H. received lecture fees from Daiichi-Sankyo Co., Ltd. and Bayer Yakuhin, Ltd."

"Funding This study was supported financially by Bayer Yakuhin, Ltd (grant number: 1286981-000)."